Showing 2381-2390 of 5771 results for "".
- Kala Pharmaceuticals Announces NDA for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by FDAhttps://modernod.com/news/kala-pharmaceuticals-announces-nda-for-kpi-121-0-25-for-dry-eye-disease-has-been-accepted-for-review-by-fda/2476240/Kala Pharmaceuticals announced that the new drug application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a 2-week course of therapy, has been accepted for review by the FDA. The FDA has set a target action date under the
- ProQR Announces Publication of QR-110 Data for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-of-qr-110-data-for-lebers-congenital-amaurosis-10/2479608/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Potential Avastin Biosimilarhttps://modernod.com/news/innovent-announces-two-clinical-studies-with-the-anti-vegf-monoclonal-antibody-ibi305-a-potential-avastin-biosimilar/2479615/Innovent Biologics announced that IBI305, a recombinant humanized anti-VEGF monoclonal antibody being developed as a potential biosimilar to Avastin (bevacizumab), has met predefined primary endpoints in two randomized, head to head, clinical trials comparing IBI30
- Santen Announces Scottish Medicines Consortium Approval of Verkazia for Severe Vernal Keratoconjunctivitishttps://modernod.com/news/santen-announces-scottish-medicines-consortium-approval-of-verkazia-for-severe-vernal-keratoconjunctivitis/2476148/Santen UK announced that the Scottish Medicines Consortium (SMC) has approved Verkazia eye drops emulsion containing 0.1% (1mg/ml) ciclosporin for use by NHS Scotland for the treatment of the rare disease, severe vernal keratoconjun
- 4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Sciencehttps://modernod.com/news/4d-molecular-therapeutics-announces-collaboration-to-advance-gene-therapies-for-retinal-diseases-with-oregon-health-science/2476157/4D Molecular Therapeutics (4DMT) announced a research and development collaboration with the Casey Eye Institute and the Oregon National Primate Research Center at Oregon Health & Science University (OHSU). The collaboration will combine the complementary expertise of 4D Molecular Therapeutic
- ATPO Announces Jessica Barr as New Presidenthttps://modernod.com/news/atpo-announces-jessica-barr-as-new-president/2476160/The Association of Technical Personnel in Ophthalmology (ATPO) has announced that Jessica Barr, COMT, ROUB, is its new president. Ms. Barr is an Implementation Specialist and Education Liaison fo
- Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategyhttps://modernod.com/news/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-for-ons-5010-clinical-strategy/2476161/Oncobiologics announced several key corporate events that enhance the company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (AMD). These events are in c
- Editas Medicine Announces FDA Acceptance of IND Application for LCA10 Treatment EDIT-101https://modernod.com/news/editas-medicine-announces-fda-acceptance-of-ind-application-for-lca10-treatment-edit-101/2476163/Editas Medicine announced that the FDA has accepted the company’s investigational new drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). “The FDA’s acceptance of our IND for
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Bausch + Lomb Announces Exclusive Agreement with Modulight to Develop New Photodynamic Laserhttps://modernod.com/news/bausch-lomb-announces-exclusive-agreement-with-modulight-to-develop-new-photodynamic-laser/2476166/Bausch + Lomb and Modulight, a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s Visudyne (verteporfin for injection)